IC
CAPR icon

Ikarian Capital’s Capricor Therapeutics CAPR Stock Holding History

Ikarian Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.1M Sell
528,015
-50,000
-9% -$1.33M 1.3% 18
2025
Q4 		$16.7M Buy
578,015
+313,373
+118% +$4.09M 1.3% 20
2025
Q3 		$1.91M Buy
+264,642
New +$1.95M 0.19% 102
2024
Q4 		– Sell
-300,000
Closed -$5.26M – 181
2024
Q3 		$4.56M Buy
+300,000
New +$1.48M 0.64% 46

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital's CAPR Position: Q1 2026 in Review

Ikarian Capital reduced its Capricor Therapeutics (CAPR) stake by 8.7% in Q1 2026, selling an estimated $1.33M and leaving 528,015 shares worth $16.1M. The position accounts for 1.3% of the portfolio, ranked #18.

Ikarian Capital first reported a position in CAPR in Q3 2024 and has held it in 4 quarters since. The position peaked at $16.7M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Ikarian Capital held 528,015 shares of Capricor Therapeutics worth $16.1M as of Q1 2026.
  • Ikarian Capital sold 50,000 Capricor Therapeutics shares in Q1 2026, an estimated $1.33M.
  • Capricor Therapeutics made up 1.3% of Ikarian Capital's portfolio in Q1 2026, its #18 holding.
  • Ikarian Capital first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Ikarian Capital's Capricor Therapeutics position peaked at $16.7M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.